Apr 25 |
Ionis Publishes 2023 Corporate Responsibility Report
|
Apr 23 |
Ionis to hold first quarter 2024 financial results webcast
|
Apr 10 |
Wolfe upgrades Ionis to outperform, cites upcoming catalysts
|
Apr 8 |
Ionis experimental drug meets key goal in familial chylomicronemia study
|
Apr 7 |
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
|
Mar 28 |
Ionis to hold olezarsen Phase 3 data webcast
|
Mar 25 |
Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?
|
Mar 25 |
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
|
Mar 22 |
Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?
|
Mar 21 |
New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding
|